August 13, 2025Breast Cancer Basic and Clinical ResearchOpen Access

The Role of Axillary Lymph Node Dissection in Breast Cancer Patients With Residual Nodal Disease After Receiving Neoadjuvant Chemotherapy

View Full Paper

Ask AI

Bookmark

Authors

KSKristina Shaffer LHLilian HarrisNovant Health LGLori F. GentileNovant Health

Discussion

Member takes

Implication

Retrospective review evaluates axillary management and oncologic outcomes in breast cancer patients, suggesting no survival benefit from ALND over SLNB.

Key Points

Axillary lymph node dissection did not improve survival or recurrence outcomes compared to sentinel lymph node biopsy.
Overall survival rates were nearly identical: 68.6% for ALND and 70.6% for SLNB, with no significant difference at P = 1.
Analysis included 155 patients, predominantly receiving neoadjuvant chemotherapy and followed for a median of 56 months.
Lymphedema rates were significantly higher in the ALND group at 57.9%, compared to 35.3% for SLNB, indicating a treatment risk.

Cite This Study

Shaffer et al. (2025) studied this question.

synapsesocial.com/papers/68c23595b210217d64771660 https://doi.org/10.1177/11782234251352996

View Full Paper

Ask AI

Bookmark

Implication

Retrospective review evaluates axillary management and oncologic outcomes in breast cancer patients, suggesting no survival benefit from ALND over SLNB.

The Role of Axillary Lymph Node Dissection in Breast Cancer Patients With Residual Nodal Disease After Receiving Neoadjuvant Chemotherapy

Discussion

Member takes

Implication

Key Points

Cite This Study

The Role of Axillary Lymph Node Dissection in Breast Cancer Patients With Residual Nodal Disease After Receiving Neoadjuvant Chemotherapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider